

Congestive Heart Failure Market Size in the 7MM was around USD 6,900 million in 2023, estimated DelveInsight

Congestive Heart Failure Market

DELHI, DELHI, INDIA, June 27, 2024 /EINPresswire.com/ -- DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.



Congestive Heart Failure Market

Explore the intricate details of the Congestive Heart Failure Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Congestive Heart Failure Market Forecast. Click here to stay ahead in healthcare innovation @ [Congestive Heart Failure Market Size](#)

Key Takeaways from the Congestive Heart Failure Market Report

- June 2024:-Sarfez Pharmaceuticals, Inc.- This research study is being done to compare the effectiveness two drugs: an extended release torsemide (ERT) versus generic immediate release Torsemide (IRT) in reducing the worsening of symptoms of Overactive Bladder (OAB i.e., frequency, urgency, or urgency incontinence) in patients with chronic congestive heart failure (CHF).
- June 2024:- Novartis Pharmaceuticals- A Multi-center, Randomized, Placebo- and Active-controlled, Parallel-group, 24-week Proof of Concept and Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Heart Failure. This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
- The analysis of CHF in the 7MM draws a clear scenario which showed that the patients with HFpEF have a larger proportion (i.e., ~50%) because the heart is not severely affected but keeps on working through medication or symptomatic treatment, whereas, in the case of HFrEF, the

patient's heart is majorly affected. With growing age, the pumping rate of the heart declines.

- In 2023, among all the four New York Heart Association (NYHA) Classes of heart failure, Class II accounted for around 45% of the total diagnosed heart failure cases in the 7MM.
- Maximum cases of heart failure fall in the age group of ≥ 60 years. In 2023, approximately 6.8 million cases of heart failure in the US belonged to this age group.
- The leading Congestive Heart Failure Companies such as Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, and others.
- Promising Congestive Heart Failure Therapies such as Furosemide, Torsemide, Bumetanide, Dapagliflozin, AB-1002, OPC 131461 10mg group, Kcentra, and others.

Delve deep into the Congestive Heart Failure Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Congestive Heart Failure Market Forecast. Click here to shape the future @ [Congestive Heart Failure Treatment Market](#)

Congestive Heart Failure Epidemiology Insights

- total diagnosed prevalent cases
- gender-specific cases
- age-specific cases
- NYHA class-specific cases
- ejection fraction-specific cases
- type-specific cases of heart failure (acute and chronic)

Navigate the complexities of the Congestive Heart Failure Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Congestive Heart Failure Market Forecast. Click here to get more insights @ [Congestive Heart Failure Prevalence](#)

Congestive Heart Failure Marketed Drugs

- ENTRESTO: Novartis

ENTRESTO combines a neprilysin inhibitor and an angiotensin II receptor blocker. In July 2015, the US FDA approved sacubitril with valsartan to reduce the risk of cardiovascular (CV) death and hospitalization in patients with CHF (NYHA Class II-IV) associated with reduced ejection fraction and got expanded approval in October 2019 and February 2021 for pediatric patients aged ≥ 1 with symptomatic heart failure with systemic left ventricular systolic dysfunction and adult patients with CHF respectively. ENTRESTO captured the major share of the CHF market in 2022.

- JARDIANCE: Boehringer Ingelheim and Eli Lilly

JARDIANCE is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The candidate is also being investigated in pivotal trials for heart failure post myocardial infarction and chronic kidney disease. In June 2021, Boehringer Ingelheim and Eli Lilly and Company announced that the European Commission had granted marketing authorization for JARDIANCE (empagliflozin) as a treatment for adults with symptomatic chronic HFrEF. Later in August 2021, it was approved by

the US FDA. US FDA had granted Breakthrough Therapy designation based on results from the Phase III EMPEROR-Preserved trial. In the last year, JARDIANCE grabbed regulatory approval from all the major regulatory bodies (FDA, EMA, and PMDA) for the treatment of chronic heart failure in patients with HFpEF, thereby extending its targeted niche.

Emerging Congestive Heart Failure Drugs

- KERENDIA (finerenone): Bayer

Finerenone (BAY 94-8862) is an investigational novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many harmful effects of mineralocorticoid receptor (MR) overactivation, which is a major driver of kidney and heart damage. The drug has received regulatory approval in the US, Canada, and the EU to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes. The drug is currently in a Phase III FINEARTS-HF trial in patients with heart failure and left ventricular ejection fraction greater or equal to 40%. FINEARTS-HF is currently the largest outcome trial investigating an MRA in HFpEF.

- MOUNJARO (tirzepatide): Eli Lilly and Company

Tirzepatide (LY3298176) is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In May 2022, tirzepatide was approved by the US FDA as a treatment for adults with type 2 diabetes. Currently, the drug is in the Phase III stage of the clinical development program evaluating its safety and efficacy in participants with HFpEF and obesity. This drug has true potential and is expected to garner the maximum revenue by 2034.

Explore More About Ongoing Pipeline Development Activities: New Drugs of Congestive Heart Failure- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Congestive Heart Failure Drug Market

The primeval drug classes like ACE inhibitors, ARBs, beta-blockers, and diuretics are still at the forefront of the heart failure treatment space. Furthermore, off-label usage of other therapies such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, and nitrates, are also high in patients affected by heart failure. The majority of therapies are prescribed in combination, and beta-blockers are one of the most prescribed classes. Among the approved therapies, ENTRESTO is Novartis' one of the most important drugs, and its revenue is expected to rise in the next few years. At present, ENTRESTO leads the CHF market among the approved therapies. After a slow beginning, ENTRESTO has emerged as one of Novartis' most important growth drivers. With the current approval in preserved ejection fraction, ENTRESTO is getting bigger and better.

Congestive Heart Failure Market Outlook

After a scarcity of sustainable new therapies for more than a decade, new classes of agents for the treatment of patients with CHF were approved by the US FDA – ENTRESTO (sacubitril/valsartan), a combined angiotensin receptor-neprilysin inhibitor (ARNI) and CORLANOR (ivabradine), a sinoatrial node modulator. Both drugs are recommended for use as part of a comprehensive medical therapy regimen. Recently approved VERQUVO (vericiguat), from Merck Pharma, in January 2021 is the newest addition for treating heart failure. The drug is indicated to reduce the risk of cardiovascular death, heart failure hospitalizations, or the need for outpatient intravenous diuretics. It is recommended in adults with symptomatic chronic heart failure and less than 45% ejection fraction. VERQUVO is a stimulator of soluble guanylate cyclase. In a recent update from the Heart Failure Association on SGLT2 inhibitors in heart failure, dapagliflozin or empagliflozin are recommended to reduce the risk of heart failure hospitalization and cardiovascular death in HFrEF patients already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus. Therefore, the current treatment landscape for this patient pool includes a range of drugs with a variable mechanism of action, offering safe and tolerable treatment options. Recently, some approved drugs also got the label expansion for treating CHF in pediatric and adult patients.

Unlock insights into the Congestive Heart Failure Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Congestive Heart Failure Market Forecast. Click here @ Congestive Heart Failure Market Drivers and Barriers- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Congestive Heart Failure Market Report

- Coverage- 7MM
- Congestive Heart Failure Companies - Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, and others.
- Congestive Heart Failure Therapies- Furosemide, Torsemide, Bumetanide, Dapagliflozin, AB-1002, OPC 131461 10mg group, Kcentra, and others.
- Congestive Heart Failure Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Congestive Heart Failure Unmet Needs, KOL's views, Analyst's views, Congestive Heart Failure Market Access and Reimbursement

Gain a strategic edge in the Congestive Heart Failure Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Congestive Heart Failure Market Forecast. Click here to lead in advancements @ Congestive Heart Failure Clinical Trials Assessment- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

- 1 Key Insights
- 2 Report Introduction
- 3 Executive Summary of Congestive Heart Failure (CHF)
- 4 Key Events
- 5 Epidemiology and Market Forecast Methodology
- 6 Congestive Heart Failure (CHF) Market Overview At A Glance
- 7 Disease Background and Overview
- 8 Treatment
- 9 Heart Failure with Preserved Ejection Fraction: Diagnosis and Management (2017)
- 10 Guidelines
- 11 Epidemiology and Patient Population
- 12 Patient Journey
- 13 Marketed Drugs
- 14 Emerging Drugs
- 15 Congestive Heart Failure (CHF): 7MM Analysis
- 16 Unmet Needs
- 17 Swot Analysis
- 18 Kol Views
- 19 Market Access and Reimbursement
- 20 Appendix
- 21 Delveinsight Capabilities
- 22 Disclaimer

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/723370397>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.